Ilyang Pharmaceutical Co Ltd

Ilyang Pharmaceutical maintains a conservative capital structure with a debt-to-equity ratio of 0.4, indicating a relatively low reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.9, suggesting limited short-term liquidity cushion. Free cash flow of 3.2 billion KRW supports operational flexibility, though cash and equivalents of 14.4 billion KRW are modest relative to total liabilities of 246.6 billion KRW.

Profitability metrics show a muted performance, with a return on equity (ROE) of 0.82% and return on assets (ROA) of 0.39%, both below the typical thresholds for pharmaceutical firms. The gross margin of 43.6% (25.6 billion KRW gross profit on 58.7 billion KRW revenue) is in line with industry norms, but operating margin of 3.6% (2.1 billion KRW operating income) reflects high operating costs or competitive pressures.

Geographically, Ilyang's revenue is concentrated in South Korea, with no material international operations disclosed. Segment-wise, the company operates as a single business unit, with no material diversification across therapeutic areas or product lines. This concentration increases exposure to domestic regulatory and reimbursement risks.

Growth appears to be flat, with revenue of 58.7 billion KRW in the latest period and no significant YoY growth disclosed. Analyst estimates for revenue and EPS align closely with reported figures, suggesting limited upside in the near term. The company's capital expenditure of -1.3 billion KRW indicates asset disposals or non-capitalized expenses, which may reflect a strategic shift or cost-cutting.

Risk factors include a negative net cash position after subtracting total debt, which could constrain flexibility in capital allocation or M&A. Dilution risk is assessed as low, with no material share issuance or ATM programs disclosed. However, the company's high price-to-earnings ratio of 93.26 suggests market expectations of future earnings growth that may not materialize.

Recent filings and transcripts show no material changes in strategy or product pipeline. The company continues to focus on domestic market expansion and cost optimization. No new drug approvals or major partnerships were disclosed in the latest period.

Ilyang Pharmaceutical Co Ltd (007570.KS) has undergone a significant update to its corporate taxonomy, now formally classified under the "Pharmaceuticals & Medical Research" activity within the broader "Healthcare" economic sector. This reclassification represents a medium-severity change in the company's profile, establishing a clearer framework for understanding its operational focus and industry alignment. Alongside the sectoral update, the company's risk assessment profile has been initialized with specific metrics. The dilution risk is now assessed as "low," indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment provides investors with a baseline for evaluating the security of their equity position. Conversely, the liquidity risk has been classified as "medium." This designation suggests that while the company maintains operational viability, there may be moderate constraints or volatility in its ability to meet short-term financial obligations or trade volume expectations. This metric is crucial for traders and investors monitoring the ease of entering or exiting positions. The company currently operates with a lean governance structure, featuring only one officer, and lacks coverage from financial analysts or inclusion in major market indices. With no top holders identified, the stock appears to have limited institutional scrutiny, making the newly established risk and taxonomy classifications particularly important for independent investors assessing the firm's fundamental standing.

Operating income surged 209.1% year-over-year, demonstrating a significant recovery in core profitability for the latest fiscal period.

Free cash flow increased by 125.6% year-over-year, indicating a substantial improvement in cash generation capabilities recently.

Net income grew 103.2% year-over-year, reflecting a strong rebound in bottom-line earnings compared to the prior year.

The debt-to-equity ratio of 0.4 is below the pharmaceutical cohort median of 0.18, suggesting a conservative leverage position.

Dilution risk is assessed as low, providing some protection for existing shareholders against equity value erosion.

Revenue declined 11.0% year-over-year, signaling a contraction in top-line sales growth for the most recent period.

Credit risk is flagged as high, indicating significant potential concerns regarding the company's ability to meet debt obligations.

Liquidity risk is rated as medium, suggesting potential challenges in meeting short-term financial obligations comfortably.

Revenue KRW 78.91B, −4,2% YoY; Operating income −73,0% YoY.

• ▍Revenue KRW 78.91B, −4,2% YoY
• ▍Operating income −73,0% YoY
• ▍Net income −315,0% YoY
• ▍Free cash flow +57,4% YoY
• ▍Net margin -7.2%

Revenue KRW 68.83B, −0,4% YoY; Operating income −103,6% YoY.

• ▍Revenue KRW 68.83B, −0,4% YoY
• ▍Operating income −103,6% YoY
• ▍Net income +141,7% YoY
• ▍Free cash flow +163,5% YoY
• ▍Net margin 12.3%

Revenue KRW 62.70B, +7,2% YoY; Operating income +6,1% YoY.

• ▍Revenue KRW 62.70B, +7,2% YoY
• ▍Operating income +6,1% YoY
• ▍Net income −45,6% YoY
• ▍Free cash flow +51,3% YoY
• ▍Net margin 0.9%

Revenue KRW 61.98B, +5,5% YoY; Operating income +63,4% YoY.

• ▍Revenue KRW 61.98B, +5,5% YoY
• ▍Operating income +63,4% YoY
• ▍Net income +90,7% YoY
• ▍Free cash flow +46,2% YoY
• ▍Net margin 5.7%

Revenue KRW 82.40B; Operating income KRW 2.07B.

• ▍Revenue KRW 82.40B
• ▍Operating income KRW 2.07B
• ▍Net margin 3.2%

Revenue KRW 69.09B; Operating income KRW 4.34B.

• ▍Revenue KRW 69.09B
• ▍Operating income KRW 4.34B
• ▍Net margin 5.1%

Revenue KRW 58.47B; Operating income KRW 1.11B.

• ▍Revenue KRW 58.47B
• ▍Operating income KRW 1.11B
• ▍Net margin 1.8%

Revenue KRW 58.72B; Operating income KRW 2.10B.

• ▍Revenue KRW 58.72B
• ▍Operating income KRW 2.10B
• ▍Net margin 3.2%

Revenue KRW 272.42B, +1,4% YoY; Operating income −48,0% YoY.

• ▍Revenue KRW 272.42B, +1,4% YoY
• ▍Operating income −48,0% YoY
• ▍Net income −23,6% YoY
• ▍Free cash flow +108,8% YoY
• ▍Net margin 2.5%

Revenue KRW 268.68B, +0,8% YoY; Operating income +12 004,7% YoY.

• ▍Revenue KRW 268.68B, +0,8% YoY
• ▍Operating income +12 004,7% YoY
• ▍Net income +475,0% YoY
• ▍Free cash flow −102 345,6% YoY
• ▍Net margin 3.4%

Revenue KRW 266.67B, +7,6% YoY; Operating income −100,6% YoY.

• ▍Revenue KRW 266.67B, +7,6% YoY
• ▍Operating income −100,6% YoY
• ▍Net income −112,4% YoY
• ▍Free cash flow −99,9% YoY
• ▍Net margin -0.9%

Revenue KRW 247.77B, +2,2% YoY; Operating income −8,1% YoY.

• ▍Revenue KRW 247.77B, +2,2% YoY
• ▍Operating income −8,1% YoY
• ▍Net income +38,1% YoY
• ▍Free cash flow +357,9% YoY
• ▍Net margin 7.8%